Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC

Vera Kloten(Bayer (Germany)), Thomas Schlange(Boehringer Ingelheim (Germany))
Cells
August 1, 2019
Cited by 99


Related Papers